Retatrutide_40mg

Retatrutide (LY3437943) is an experimental weight loss medication developed by Eli Lilly. It stands out by targeting three hormone receptors—GLP-1, GIP, and glucagon—offering a comprehensive approach to appetite control, fat burning, and metabolic regulation. In Phase 2 clinical trials, participants administered weekly doses of retatrutide experienced significant weight loss, with the 12 mg dose resulting in an average reduction of 24.2% over 48 weeks. Additionally, improvements in blood sugar levels, insulin sensitivity, and blood pressure were observed. While the drug shows promise, potential side effects such as gastrointestinal discomfort and increased heart rate have been noted, particularly at higher doses. Retatrutide is currently undergoing further clinical trials, with FDA approval anticipated in the coming years.